Osteoarthritis - Market sees steady growth

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The 2004 withdrawal of Vioxx from the global market had a negative effect on the COX-2 class, with a 44% fall in Celebrex sales for osteoarthritis in 2005. However, as patients sought an alternative to the COX-2s, there was positive growth in traditional NSAIDs, non-narcotic analgesics, narcotic analgesics, corticosteroids and HA viscosupplements, leading to a 1.1% increase in total market value.


Scope

  • Sales and volume forecasts for the leading osteoarthritis therapies to 2015, calculated for the osteoarthritis indication alone
  • Assessment of current and future opportunities and threats in the osteoarthritis market across the seven major pharmaceutical markets
  • Key events that may affect revenues are applied and discussed for each of the seven major pharmaceutical markets.
  • Case studies outline future strategies companies will use for advertising and marketing COX-2 inhibitors and the factors behind the success of Synvisc


    • Report Highlights
    The osteoarthritis market is forecast to grow steadily, and will reach $7 billion by 2015. Growth comes from expanded use of hyaluronic acids and pipeline products launches. Despite competition from COX-2s such as Prexige and Arcoxia, Pfizer's Celebrex to remain the leading brand until patent expiry in 2014.

    After the withdrawal of Vioxx over CV safety fears, Merck was criticized for its heavy marketing campaign. Companies should target their products to specific populations rather than the population as a whole, shift to eSampling and continue to conduct large-scale safety studies.

    Synvisc sales will reach $300 million by 2015. Indication expansions in the US and EU, and launch in Japan, will drive sales. Future opportunities in the HA market will come from the development of single injection products. The EU markets show good opportunity for HAs with the highest growth.


    Reasons to Purchase

  • Assess the impact of events such as patent expiries and indication expansion on the osteoarthritis sales of key brand name products
  • Quantify the future size of the market, in terms of volume and value, for the osteoarthritis indication in each of the seven major markets
  • Understand strategies that pharmaceutical companies will use to market COX-2s in the future

    • Table of Contents

    Other users found this report page using the following search terms: osteoarthritis arthritis market osteoarthritis size sales arthrotec patent viscosupplementation synvisc expiry celebrex

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.